Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: A real-world cohort
Drug Design, Development and Therapy Aug 09, 2017
Bernuth S, et al. – The efficacy and safety of new interferon (IFN)–free direct–acting antiviral (DAA) therapies were examined in patients with hepatitis C virus (HCV) infection after liver transplantation (LT). Outcomes confirmed that DAA therapy was effective and safe in HCV infection patients after LT.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
